SAN ANTONIO (EGMN) - Using a combination of gene expression signature and copy number signature analyses, clinicians may some day be able to predict the likelihood of metastasis in patients with lymph node-negative primary breast cancers, John A. Foekens, Ph.D., reported at the annual San Antonio Breast Cancer Symposium.A total of 90% of patients with both favorable copy number and gene expression signatures lived 5 years without experiencing metastasis in a study conducted by Dr. Foekens of the...